Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec 1;110(12):8045-8056.
doi: 10.1097/JS9.0000000000001826.

Efficacy and safety of robotic vs. laparoscopic gastrectomy for patients with gastric cancer: systematic review and meta-analysis

Affiliations
Meta-Analysis

Efficacy and safety of robotic vs. laparoscopic gastrectomy for patients with gastric cancer: systematic review and meta-analysis

Zhenshun Li et al. Int J Surg. .

Abstract

Background: The emergence of robotic surgical systems compensated for the technological shortcomings of laparoscopic approaches. However, whether robotic gastrectomy (RG) has better perioperative outcomes and survival than laparoscopic gastrectomy (LG) for gastric cancer (GC) is still unclear but increasingly drawing attention.

Materials and methods: In this systematic review and meta-analysis, we searched PubMed, EMBASE, Web of Science, and Cochrane Library as of 20 January 2024, and referenced a list of eligible articles for all published studies comparing RG and LG for patients with GC. Data on study characteristics, individual characteristics, and outcome parameters were extracted. The quality of studies was assessed using the Revised Cochrane risk-of-bias 2 tool and the risk of bias in nonrandomized studies of interventions tool. The main outcome measures were overall survival (OS) and disease-free survival (DFS).

Results: The authors identified 3641 articles, of which 72 studies (30 081 patients) were included in the meta-analysis. Compared with LG, RG was associated with higher OS [hazard ratio (HR)=0.89, 95% CI=0.83-0.96], lower rate of overall postoperative complications [odds ratio (OR)=0.77, 95% CI=0.71-0.84], longer operating time [mean difference (MD)=35.53, 95% CI=29.23-41.83], less estimated blood loss (MD=-37.45, 95% CI=-46.24 to -28.67), a higher number of retrieved lymph nodes (MD=1.88, 95% CI=0.77-3.00), faster postoperative recovery, and lower rate of conversion (OR=0.44, 95% CI=0.36-0.55). Mortality and DFS were not significantly different between the two groups. The subgroup of meta-analysis results also showed the advantages of robotic surgery over laparoscopic surgery in intracorporeal reconstruction, total gastrectomy, Ⅰ/Ⅱ stage, and BMI≥25, especially for patients with stage Ⅰ/Ⅱ, there are better OS and DFS.

Conclusion: Our findings point to robotic surgery having great benefits compared with laparoscopic surgery in GC. Our study may help inform decision-making in applying robotic surgical systems to clinical treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Figures

Figure 1
Figure 1
Flowchart of the study screening and evaluation process.
Figure 2
Figure 2
Forest plot of the meta-analysis for overall survival and disease-free survival. (A), overall survival, (B), disease-free survival.
Figure 3
Figure 3
Forest plot of the meta-analysis for complications. (A) overall. complications, (B), CD≥Ⅲ complications, (C), anastomosis leakage, (D), intra-abdominal abscess/fluid collection; (E), pulmonary infection; (F), pancreatic fistula; (G), intra-abdominal bleeding.
Figure 4
Figure 4
Forest plot of the meta-analysis for surgical outcomes. (A), operating time, (B), estimated blood loss, (C), number of retrieved lymph nodes, (D), conversion; (E) mortality.
Figure 5
Figure 5
Forest plot of the meta-analysis for postoperative outcomes. (A), postoperative hospitalization stay, (B), time to first flatus, (C), time to first liquid or oral diet.
Figure 6
Figure 6
Forest plot of the meta-analysis for total cost.

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249. - PubMed
    1. Bang YJ, Kim YW, Yang HK, et al. . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315–321. - PubMed
    1. Cats A, Jansen EPM, van Grieken NCT, et al. . Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616–628. - PubMed
    1. Wang F, Wei XL, Wang FH, et al. . Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol 2019;30:1479–1486. - PMC - PubMed
    1. Japanese Gastric Cancer Association . Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 2023;26:1–25. - PMC - PubMed

MeSH terms